Trial watch: Dendritic cell-based anticancer immunotherapy

OncoImmunology

Volumn 6, Issue 7, 2017, Pages

  Garg, Abhishek D ^a   Vara Perez, Monica ^a   Schaaf, Marco ^a   Agostinis, Patrizia ^a   Zitvogel, Laurence ^b,c,d,e   Kroemer, Guido ^{b,f,g,h,i,j,k}   Galluzzi, Lorenzo ^f,l  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c University Paris XI   (France)

^d Center of Clinical Investigations in Biotherapies of Cancer (CICBT)   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h CENTRE DE RECHERCHE DES CORDELIERS   (France)

ⁱ INSERM   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

Antigen cross presentation; DAMPs; immune checkpoint blockers; plasmacytoid dendritic cells; TLR signaling; tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION ASSAY; CLINICAL TRIAL (TOPIC); GENE; HUMAN; LIVER CELL CARCINOMA; LUNG CARCINOMA; MAGE GENE; MYCOBACTERIUM TUBERCULOSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC);

EID: 85021431664     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1328341     Document Type: Article

References (245)

1. Lanzavecchia A, Sallusto F, Ralph M. Steinman 1943–2011. Cell 2011; 147:1216-7; PMID:22263224; https://doi.org/10.1016/j.cell.2011.11.040
2. Nussenzweig MC, Mellman I. Ralph Steinman (1943–2011). Nature 2011; 478:460; PMID:22031432; https://doi.org/10.1038/478460a
3. Mellman I, Nussenzweig M. Retrospective. Ralph M. Steinman (1943–2011). Science 2011; 334:466; PMID:22034425; https://doi.org/10.1126/science.1215136
4. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62; PMID:4573839; https://doi.org/10.1084/jem.137.5.1142
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; https://doi.org/10.1038/32588
6. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; https://doi.org/10.1038/nature06175
7. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage:Ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604; PMID:23516985; https://doi.org/10.1146/annurev-immunol-020711-074950
8. Dudek AM, Martin S, Garg AD, Agostinis P. Immature, semi-mature, and fully mature dendritic cells:Toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol 2013; 4:438; PMID:24376443; https://doi.org/10.3389/fimmu.2013.00438
9. Morello S, Pinto A, Blandizzi C, Antonioli L. Myeloid cells in the tumor microenvironment:Role of adenosine. OncoImmunology 2016; 5:e1108515; PMID:27141365; https://doi.org/10.1080/2162402X.2015.1108515
10. Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81; PMID:20479115; https://doi.org/10.1084/jem.20100348
11. Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset AK, Marvel J, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1283-92; PMID:20479118; https://doi.org/10.1084/jem.20100223
12. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60; PMID:20479116; https://doi.org/10.1084/jem.20092140
13. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1261-71; PMID:20479117; https://doi.org/10.1084/jem.20092618
14. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; https://doi.org/10.1038/nri3254
15. Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev 2010; 234:18-31; PMID:20193009; https://doi.org/10.1111/j.0105-2896.2009.00870.x
16. Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, Kiss M, Bolli E, Lahmar Q, Sichien D, et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun 2016; 7:13720; PMID:28008905; https://doi.org/10.1038/ncomms13720
17. Di Blasio S, Wortel IMN, van Bladel DAG, de Vries LE, Duiveman-de Boer T, Worah K, de Haas N, Buschow SI, de Vries IJ, Figdor CG, et al. Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death. OncoImmunology 2016; 5:e1192739; PMID:27622063; https://doi.org/10.1080/2162402X.2016.1192739
18. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29:497-510; PMID:18789730; https://doi.org/10.1016/j.immuni.2008.07.013
19. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, Di Pucchio T, Connolly J, Fay JW, Pascual V, et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219:118-42; PMID:17850486; https://doi.org/10.1111/j.1600-065X.2007.00551.x
20. Van Acker HH, Anguille S, Van Tendeloo VF, Lion E. Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy. OncoImmunology 2015; 4:e1021538; PMID:26405575; https://doi.org/10.1080/2162402X.2015.1021538
21. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-7; PMID:10364556; https://doi.org/10.1126/science.284.5421.1835
22. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1:305-10; PMID:11017101; https://doi.org/10.1038/79747
23. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, O'Garra A, Liu YJ. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 2002; 195:953-8; PMID:11927638; https://doi.org/10.1084/jem.20020045
24. van Beek JJP, Gorris MAJ, Sköld AE, Hatipoglu I, Van Acker HH, Smits EL, de Vries IJ, Bakdash G. Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. OncoImmunology 2016; 5:e1227902; PMID:27853652; https://doi.org/10.1080/2162402X.2016.1227902
25. Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, Mucida D, Merad M, Steinman RM. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013; 123:844-54; PMID:23298832; https://doi.org/10.1172/JCI65260
26. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:12615891; https://doi.org/10.1146/annurev.immunol.21.120601.141040
27. Garg AD, Romano E, Rufo N, Agostinis P. Immunogenic versus tolerogenic phagocytosis during anticancer therapy:Mechanisms and clinical translation. Cell Death Differ 2016; 23:938-51; PMID:26891691; https://doi.org/10.1038/cdd.2016.5
28. Maddur MS, Bayry J. B cells drive Th2 responses by instructing human dendritic cell maturation. OncoImmunology 2015; 4:e1005508; PMID:26155405; https://doi.org/10.1080/2162402X.2015.1005508
29. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; https://doi.org/10.1038/nrc3258
30. Fellermeier S, Beha N, Meyer J-E, Ring S, Bader S, Kontermann RE, Müller D. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. OncoImmunology 2016; 5:e1238540; PMID:27999756; https://doi.org/10.1080/2162402X.2016.1238540
31. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; https://doi.org/10.1038/nm.3708
32. Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs:What, when, and how? Biofactors 2013; 39:355-67; PMID:23900966; https://doi.org/10.1002/biof.1125
33. Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol 2015; 6:588; PMID:26635802; https://doi.org/10.3389/fimmu.2015.00588
34. Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, et al. Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front Immunol 2015; 6:402; PMID:26300886; https://doi.org/10.3389/fimmu.2015.00402
35. Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol 2015; 6:187; PMID:25964783; https://doi.org/10.3389/fimmu.2015.00275 10.3389/fimmu.2015.00187
36. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. DAMP - induced allograft and tumor rejection:The circle is closing. Am J Transplant 2016; 16:3322-37; PMID:27529775; https://doi.org/10.1111/ajt.14012
37. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and damage-associated molecular patterns (DAMPs). Am J Transplant 2016; 16:3338-61; PMID:27421829; https://doi.org/10.1111/ajt.13963
38. Garg AD, Vandenberk L, Fang S, Fasche T, Van Eygen S, Maes J, Van Woensel M, Koks C, Vanthillo N, Graf N, et al. Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. Cell Death Differ 2017; 24:832-843; PMID:28234357; https://doi.org/10.1038/cdd.2017.15
39. Baert T, Garg AD, Vindevogel E, A VANH, Verbist G, Agostinis P, Vergote I, Coosemans AN. In vitro generation of murine dendritic cells for cancer immunotherapy:An optimized protocol. Anticancer Res 2016; 36:5793-801; PMID:27793901; https://doi.org/10.21873/anticanres.11163
40. Stachura J, Wachowska M, Kilarski WW, Güç E, Golab J, Muchowicz A. The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. OncoImmunology 2016; 5:e1182278; PMID:27622039; https://doi.org/10.1080/2162402X.2016.1182278
41. Bol KF, Figdor CG, Aarntzen EHJG, Welzen MEB, van Rossum MM, Blokx WAM, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. OncoImmunology 2015; 4:e1019197; PMID:26405571; https://doi.org/10.1080/2162402X.2015.1019197
42. Steinman RM. Decisions about dendritic cells:Past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:22136168; https://doi.org/10.1146/annurev-immunol-100311-102839
43. Maldonado-Lopez R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, Thielemans K, Leo O, Urbain J, Moser M. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999; 189:587-92; PMID:9927520; https://doi.org/10.1084/jem.189.3.587
44. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999; 96:1036-41; PMID:9927689; https://doi.org/10.1073/pnas.96.3.1036
45. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-11; PMID:17204652; https://doi.org/10.1126/science.1136080
46. Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res 2016; 27:74-95; PMID:28025976; https://doi.org/10.1038/cr.2016.157
47. Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic cell-based immunotherapy:State of the art and beyond. Clin Cancer Res 2016; 22:1897-906; PMID:27084743; https://doi.org/10.1158/1078-0432.CCR-15-1399
48. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; https://doi.org/10.1016/S1470-2045(13)70585-0
49. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; https://doi.org/10.1016/j.immuni.2013.07.004
50. Hanoteau A, Moser M. Chemotherapy and immunotherapy:A close interplay to fight cancer? OncoImmunology 2016; 5:e1190061; PMID:27622046; https://doi.org/10.1080/2162402X.2016.1190061
51. Hargadon KM. The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity. OncoImmunology 2016; 5:e1069462; PMID:26942090; https://doi.org/10.1080/2162402X.2015.1069462
52. Toma M, Wehner R, Kloß A, Hübner L, Fodelianaki G, Erdmann K, Füssel S, Zastrow S, Meinhardt M, Seliger B, et al. Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. OncoImmunology 2015; 4:e1008342; PMID:26155414; https://doi.org/10.1080/2162402X.2015.1008342
53. Stoll G, Iribarren K, Michels J, Leary A, Zitvogel L, Cremer I, Kroemer G. Calreticulin expression:Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. OncoImmunology 2016; 5:e1177692; PMID:27622029; https://doi.org/10.1080/2162402X.2016.1177692
54. Stoll G, Bindea G, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget 2015; 6:11894-909; PMID:26059437; https://doi.org/10.18632/oncotarget.4180
55. Flies DB, Higuchi T, Harris JC, Jha V, Gimotty PA, Adams SF. Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103+ dendritic cells in late-stage ovarian cancer. OncoImmunology 2016; 5:e1185583; PMID:27622059; https://doi.org/10.1080/2162402X.2016.1185583
56. Cornwall SMJ, Wikstrom M, Musk AW, Alvarez J, Nowak AK, Nelson DJ. Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes. OncoImmunology 2016; 5:e1082028; PMID:27057464; https://doi.org/10.1080/2162402X.2015.1082028
57. Suryawanshi A, Manicassamy S. Tumors induce immune tolerance through activation of β-catenin/TCF4 signaling in dendritic cells:A novel therapeutic target for cancer immunotherapy. OncoImmunology 2015; 4:e1052932; PMID:26587326; https://doi.org/10.1080/2162402X.2015.1052932
58. Garg AD, Elsen S, Krysko DV, Vandenabeele P, de Witte P, Agostinis P. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget 2015; 6:26841-60; PMID:26314964; https://doi.org/10.18632/oncotarget.4754
59. Ye J, Peng G. Controlling T cell senescence in the tumor microenvironment for tumor immunotherapy. OncoImmunology 2015; 4:e994398; PMID:25949919; https://doi.org/10.4161/2162402X.2014.994398
60. Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, et al. The human vaccines project:A roadmap for cancer vaccine development. Sci Transl Med 2016; 8:334ps9; PMID:27075624; https://doi.org/10.1126/scitranslmed.aaf0685
61. Wimmers F, Aarntzen EHJG, Duiveman-deBoer T, Figdor CG, Jacobs JFM, Tel J, de Vries IJ. Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. OncoImmunology 2016; 5:e1067745; PMID:26942087; https://doi.org/10.1080/2162402X.2015.1067745
62. Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, et al. CMRF-56+ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. OncoImmunology 2016; 5:e1168555; PMID:27471645; https://doi.org/10.1080/2162402X.2016.1168555
63. Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, et al. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. OncoImmunology 2016; 5:e1191732; PMID:27622047; https://doi.org/10.1080/2162402X.2016.1191732
64. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203; PMID:17476349; https://doi.org/10.1172/JCI31205
65. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy:From ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802; PMID:17853902; https://doi.org/10.1038/nri2173
66. Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2:337-49; PMID:12440225; https://doi.org/10.1046/j.1359-4117.2002.01050.x
67. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59:4035-41; PMID:10463604.
68. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004; 10:2891-901; PMID:15102698; https://doi.org/10.1158/1078-0432.CCR-03-0380
69. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66:8887-96; PMID:16951206; https://doi.org/10.1158/0008-5472.CAN-05-3448
70. Endo H, Saito T, Kenjo A, Hoshino M, Terashima M, Sato T, Anazawa T, Kimura T, Tsuchiya T, Irisawa A, et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. J Hepatobiliary Pancreat Sci 2012; 19:465-75; PMID:21983893; https://doi.org/10.1007/s00534-011-0457-7
71. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70:706-15; PMID:9096653; https://doi.org/10.1002/(SICI)1097-0215(19970317)70:6%3c706::AID-IJC13%3e3.0.CO;2-7
72. DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998; 68:79-91; PMID:9624036; https://doi.org/10.1002/(SICI)1096-9098(199806)68:2%3c79::AID-JSO3%3e3.0.CO;2-H
73. DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 1998; 185:65-74; PMID:9636684; https://doi.org/10.1006/cimm.1998.1277
74. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998; 95:9482-7; PMID:9689106; https://doi.org/10.1073/pnas.95.16.9482
75. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001; 93:539-48; PMID:11477558; https://doi.org/10.1002/ijc.1365
76. Paczesny S, Beranger S, Salzmann JL, Klatzmann D, Colombo BM. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res 2001; 61:2386-9; PMID:11289101
77. Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, Osterborg A, Mellstedt H. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18:1810-5; PMID:15385926; https://doi.org/10.1038/sj.leu.2403517
78. Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Osterborg A, Mellstedt H. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003; 17:894-9; PMID:12750703; https://doi.org/10.1038/sj.leu.2402913
79. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:9510252; https://doi.org/10.1038/32183
80. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-68; PMID:9763615; https://doi.org/10.1084/jem.188.7.1359
81. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302; PMID:7489412; https://doi.org/10.1038/nm1295-1297
82. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86-94; PMID:8574470; https://doi.org/10.1097/00002371-199508000-00002
83. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357-65; PMID:8666894; https://doi.org/10.1084/jem.183.4.1357
84. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317-22; PMID:8551239; https://doi.org/10.1084/jem.183.1.317
85. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ, Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161:2094-8; PMID:9725199
86. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells:Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183:87-97; PMID:8551248; https://doi.org/10.1084/jem.183.1.87
87. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15:94-103; PMID:9090785; https://doi.org/10.1002/stem.150094
88. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions:Cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405-11; PMID:10202929; https://doi.org/10.1038/7403
89. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72; PMID:8760800; https://doi.org/10.1084/jem.184.2.465
90. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186:1177-82; PMID:9314567; https://doi.org/10.1084/jem.186.7.1177
91. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34; PMID:10706120
92. Irvine AS, Trinder PK, Laughton DL, Ketteringham H, McDermott RH, Reid SC, Haines AM, Amir A, Husain R, Doshi R, et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol 2000; 18:1273-8; PMID:11101806; https://doi.org/10.1038/82383
93. Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997; 61:125-32; PMID:9021916
94. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247-56; PMID:9334364; https://doi.org/10.1084/jem.186.8.1247
95. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or “self” antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27:2702-7; PMID:9368629; https://doi.org/10.1002/eji.1830271033
96. Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8:1355-63; PMID:9295130; https://doi.org/10.1089/hum.1997.8.11-1355
97. McArthur JG, Mulligan RC. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 1998; 21:41-7; PMID:9456435; https://doi.org/10.1097/00002371-199801000-00005
98. Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, Carbone DP. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999; 117:244-51; PMID:10444254; https://doi.org/10.1046/j.1365-2249.1999.00913.x
99. Tuting T, Steitz J, Bruck J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1999; 1:400-6; PMID:10753065; https://doi.org/10.1002/(SICI)1521-2254(199911/12)1:6%3c400::AID-JGM68%3e3.3.CO;2-4 10.1002/(SICI)1521-2254(199911/12)1:6%3c400::AID-JGM68%3e3.0.CO;2-D
100. Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, Gauldie J. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999; 198:131-8; PMID:10648127; https://doi.org/10.1006/cimm.1999.1585
101. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699-708; PMID:10811863; https://doi.org/10.1084/jem.191.10.1699
102. Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SN, Glaspy JA, McBride WH, Economou JS. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000; 23:59-66; PMID:10687138; https://doi.org/10.1097/00002371-200001000-00008
103. Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Okada Y, Fujita T, Hayakawa T, et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61:7913-9; PMID:11691812
104. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000; 165:5713-9; PMID:11067929; https://doi.org/10.4049/jimmunol.165.10.5713
105. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:10973321; https://doi.org/10.1038/79519
106. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001; 94:474-81; PMID:11235953; https://doi.org/10.3171/jns.2001.94.3.0474
107. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002; 22:613-21; PMID:12014629
108. Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, Thielemans K. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9:787-97; PMID:12189529; https://doi.org/10.1038/sj.cgt.7700499
109. Minami T, Nakanishi Y, Izumi M, Harada T, Hara N. Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. J Immunother 2003; 26:420-31; PMID:12973031; https://doi.org/10.1097/00002371-200309000-00005
110. Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res 2003; 63:8962-7; PMID:14695214
111. Jung CW, Kwon JH, Seol JG, Park WH, Hyun JM, Kim ES, Kim ST, Lee SJ, Kim BK, Lee YY. Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. Am J Hematol 2004; 75:121-7; PMID:14978690; https://doi.org/10.1002/ajh.10471
112. Liu BY, Chen XH, Gu QL, Li JF, Yin HR, Zhu ZG, Lin YZ. Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol 2004; 10:630-3; PMID:14991927; https://doi.org/10.3748/wjg.v10.i5.630
113. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170:5391-7; PMID:12759413; https://doi.org/10.4049/jimmunol.170.11.5391
114. Celluzzi CM, Falo LD, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160:3081-5; PMID:9531260
115. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516-24; PMID:9820528
116. Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002; 220:1-12; PMID:12718934; https://doi.org/10.1016/S0008-8749(03)00009-1
117. Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001; 213:4-13; PMID:11747351; https://doi.org/10.1006/cimm.2001.1864
118. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003; 225:65-74; PMID:14698141; https://doi.org/10.1016/j.cellimm.2003.09.005
119. Sukhorukov VL, Reuss R, Endter JM, Fehrmann S, Katsen-Globa A, Gessner P, Steinbach A, Müller KJ, Karpas A, Zimmermann U, et al. A biophysical approach to the optimisation of dendritic-tumour cell electrofusion. Biochem Biophys Res Commun 2006; 346:829-39; PMID:16780801; https://doi.org/10.1016/j.bbrc.2006.05.193
120. Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbe J, Bonnotte B. Dendritic cell-tumor cell hybrids and immunotherapy:What's next? Cytotherapy 2011; 13:774-85; PMID:21299362; https://doi.org/10.3109/14653249.2011.553593
121. Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, O'Donnell D, Selby P, Vile R, Melcher A. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006; 13:138-49; PMID:16136162; https://doi.org/10.1038/sj.gt.3302609
122. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; https://doi.org/10.1084/jem.20032220
123. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; https://doi.org/10.1084/jem.20021598
124. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769-79; PMID:11560993; https://doi.org/10.1084/jem.194.6.769
125. Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, et al. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371-9; PMID:17709554; https://doi.org/10.4049/jimmunol.179.5.3371
126. Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847-55; PMID:17875726; https://doi.org/10.1158/0008-5472.CAN-07-0321
127. Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278-85; PMID:15878980; https://doi.org/10.1182/blood-2005-01-0318
128. Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010; 116:1685-97; PMID:20530286; https://doi.org/10.1182/blood-2010-01-264960
129. Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33:4229-39; PMID:22410170; https://doi.org/10.1016/j.biomaterials.2012.02.036
130. Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012; 119:2284-92; PMID:22234694; https://doi.org/10.1182/blood-2011-08-373944
131. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011; 118:4111-9; PMID:21860028; https://doi.org/10.1182/blood-2011-04-346957
132. Tacken PJ, Ter Huurne M, Torensma R, Figdor CG. Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking. Eur J Immunol 2012; 42:1989-98; PMID:22653683; https://doi.org/10.1002/eji.201142258
133. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-44; PMID:21967977; https://doi.org/10.1182/blood-2011-07-367615
134. Van der Jeught K, Van Lint S, Thielemans K, Breckpot K. Intratumoral delivery of mRNA:Overcoming obstacles for effective immunotherapy. OncoImmunology 2015; 4:e1005504; PMID:26155403; https://doi.org/10.1080/2162402X.2015.1005504
135. Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy 2016; 8:315-30; PMID:26860335; https://doi.org/10.2217/imt.15.120
136. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine:Dendritic cell-derived exosomes. Nat Med 1998; 4:594-600; PMID:9585234; https://doi.org/10.1038/nm0598-594
137. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147:599-610; PMID:10545503; https://doi.org/10.1083/jcb.147.3.599
138. Viaud S, Thery C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N. Dendritic cell-derived exosomes for cancer immunotherapy:What's next? Cancer Res 2010; 70:1281-5; PMID:20145139; https://doi.org/10.1158/0008-5472.CAN-09-3276
139. Consortium E-T, Van Deun J, Mestdagh P, Agostinis P, Akay O, Anand S, Anckaert J, Martinez ZA, Baetens T, Beghein E, et al. EV-TRACK:Transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Met 2017; 14:228-32; PMID:28245209; https://doi.org/10.1038/nmeth.4185
140. Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. OncoImmunology 2016; 5:e1071008; PMID:27141373; https://doi.org/10.1080/2162402X.2015.1071008
141. Liu Y, Gu Y, Cao X. The exosomes in tumor immunity. OncoImmunology 2015; 4:e1027472; PMID:26405598; https://doi.org/10.1080/2162402X.2015.1027472
142. Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, et al. Trial watch:Immunostimulation with toll-like receptor agonists in cancer therapy. OncoImmunology 2016; 5:e1088631; PMID:27141345; https://doi.org/10.1080/2162402X.2015.1088631
143. Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, et al. Trial Watch—Immunostimulation with cytokines in cancer therapy. OncoImmunology 2016; 5:e1115942; PMID:27057468; https://doi.org/10.1080/2162402X.2015.1115942
144. Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K, Bartůňková J, Špíšek R. Poly I:C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9:223; PMID:22208910; https://doi.org/10.1186/1479-5876-9-223
145. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spísek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821-33; PMID:21602432; https://doi.org/10.1158/0008-5472.CAN-11-0950
146. Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31:101-12; PMID:18157017; https://doi.org/10.1097/CJI.0b013e318159f5ba
147. Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial Watch:Peptide-based anticancer vaccines. OncoImmunology 2015; 4:e974411; PMID:26137405; https://doi.org/10.4161/2162402X.2014.974411
148. Li M, You S, Ge W, Ma S, Ma N, Zhao C. Induction of T-cell immunity against leukemia by dendritic cells pulsed with total RNA isolated from leukemia cells. Chin Med J (Engl) 2003; 116:1655-61; PMID:14642130
149. Lee J, Boczkowski D, Nair S. Programming human dendritic cells with mRNA. Methods Mol Biol 2013; 969:111-25; PMID:23296931; https://doi.org/10.1007/978-1-62703-260-5_8
150. Garg NK, Dwivedi P, Prabha P, Tyagi RK. RNA pulsed dendritic cells:An approach for cancer immunotherapy. Vaccine 2013; 31:1141-56; PMID:23306369; https://doi.org/10.1016/j.vaccine.2012.12.027
151. Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. OncoImmunology 2016; 5:e1232237; PMID:27999747; https://doi.org/10.1080/2162402X.2016.1232237
152. Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met, Ö, Hansen M, Andersen MH, Thor Straten P, Svane IM. mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. OncoImmunology 2016; 5:e1207842; PMID:27757300; https://doi.org/10.1080/2162402X.2016.1207842
153. Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv 2013; 2013:869718; PMID:24228179; https://doi.org/10.1155/2013/869718
154. Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M, Quintin-Colonna F, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006; 36:1124-35; PMID:16568496; https://doi.org/10.1002/eji.200535443
155. Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P, et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol 2000; 165:3301-8; PMID:10975847; https://doi.org/10.4049/jimmunol.165.6.3301
156. Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21:883-90; PMID:12547598; https://doi.org/10.1016/S0264-410X(02)00536-4
157. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes:A highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64:4357-65; PMID:15205352; https://doi.org/10.1158/0008-5472.CAN-04-0138
158. Badiee A, Davies N, McDonald K, Radford K, Michiue H, Hart D, Kato M. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007; 25:4757-66; PMID:17512099; https://doi.org/10.1016/j.vaccine.2007.04.029
159. Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008; 26:326-34; PMID:18297056; https://doi.org/10.1038/nbt1390
160. Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tuting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT, et al. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res 2011; 71:5827-37; PMID:21747119; https://doi.org/10.1158/0008-5472.CAN-11-0804
161. Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl TD, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009; 27:7116-24; PMID:19786146; https://doi.org/10.1016/j.vaccine.2009.09.055
162. Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther 2005; 4:289-94; PMID:15753654; https://doi.org/10.4161/cbt.4.3.1499
163. Vindevogel E, Baert T, A VANH, Verbist G, Vande Velde G, Garg AD, Agostinis P, Vergote I, Coosemans AN. The use of toll-like receptor 4 agonist to reshape the immune signature in ovarian cancer. Anticancer Res 2016; 36:5781-92; PMID:27793900; https://doi.org/10.21873/anticanres.11162
164. Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51; PMID:24739759; https://doi.org/10.1126/scitranslmed.3008068
165. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063-75; PMID:23345163; https://doi.org/10.1158/0008-5472.CAN-12-2583
166. Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res 2016; 22:2155-66; PMID:26712687; https://doi.org/10.1158/1078-0432.CCR-15-2205
167. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67:1842-52; PMID:17293384; https://doi.org/10.1158/0008-5472.CAN-06-4038
168. Duluc D, Joo H, Ni L, Yin W, Upchurch K, Li D, Xue Y, Klucar P, Zurawski S, Zurawski G, et al. Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1. J Immunol 2014; 192:5776-88; PMID:24835401; https://doi.org/10.4049/jimmunol.1301661
169. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le Grand R, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med 2012; 209:109-21; PMID:22213806; https://doi.org/10.1084/jem.20110399
170. Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, Anguiano E, Pourpe S, Goller K, Pascual V, et al. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-beta. Immunity 2013; 38:818-30; PMID:23562160; https://doi.org/10.1016/j.immuni.2013.03.004
171. Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, et al. Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:172ra20; PMID:23408053; https://doi.org/10.1126/scitranslmed.3004888
172. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell 2016; 165:276-87; PMID:27058662; https://doi.org/10.1016/j.cell.2016.03.001
173. Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie W-R, Aft RL, Cornelius LA, Trinkaus KM, Linette GP. IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013; 123:3383-94; PMID:23867552; https://doi.org/10.1172/JCI68395
174. Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12:Still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014; 63:419-35; PMID:24514955; https://doi.org/10.1007/s00262-014-1523-1
175. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; https://doi.org/10.1056/NEJMoa1001294
176. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. Sipuleucel-T. Nat Rev Drug Discov 2010; 9:513-4; PMID:20592741; https://doi.org/10.1038/nrd3220
177. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer:The first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520-6; PMID:21471425; https://doi.org/10.1158/1078-0432.CCR-10-3126
178. Brunet LR, Hagemann T, Gaya A, Mudan S, Marabelle A. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? OncoImmunology 2016; 5:e1112942; PMID:27141395; https://doi.org/10.1080/2162402X.2015.1112942
179. Felix J, Lambert J, Roelens M, Maubec E, Guermouche H, Pages C, Sidina I, Cordeiro DJ, Maki G, Chasset F, et al. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. OncoImmunology 2016; 5:1136045; PMID:27622012; https://doi.org/10.1080/2162402X.2015.1136045
180. Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, et al. Trial watch:Tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology 2015; 4:e985940; PMID:25949870; https://doi.org/10.4161/2162402X.2014.985940
181. Kayser S, Boβ C, Feucht J, Witte K-E, Scheu A, Bülow H-J, Joachim S, Stevanović S, Schumm M, Rittig SM, et al. Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy. OncoImmunology 2015; 4:e1002723; PMID:26155389; https://doi.org/10.1080/2162402X.2014.1002723
182. Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, et al. Trial Watch:Adoptive cell transfer for oncological indications. OncoImmunology 2015; 4:e1046673; PMID:26451319; https://doi.org/10.1080/2162402X.2015.1046673
183. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519; https://doi.org/10.18632/oncotarget.2998
184. Garg AD, Vandenberk L, Van Woensel M, Belmans J, Schaaf M, Boon L, De Vleeschouwer S, Agostinis P. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. Oncoimmunology 2017; Mar 3;6(4):e1295903; PMID:28507806; https://doi.org/10.1080/2162402X.2017.1295903.
185. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519:366-9; PMID:25762141; https://doi.org/10.1038/nature14320
186. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348:803-8; PMID:25837513; https://doi.org/10.1126/science.aaa3828
187. Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, Agostinis P. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med 2016; 8:328ra27; PMID:26936504; https://doi.org/10.1126/scitranslmed.aae0105
188. Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, Daigo Y, Ogasawara K. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. Cancer Sci 2015; 106:134-42; PMID:25483888; https://doi.org/10.1111/cas.12584
189. Xiang J, Xu L, Gong H, Zhu W, Wang C, Xu J, Feng L, Cheng L, Peng R, Liu Z. Antigen-loaded upconversion nanoparticles for dendritic cell stimulation, tracking, and vaccination in dendritic cell-based immunotherapy. ACS Nano 2015; 9:6401-11; PMID:26028363; https://doi.org/10.1021/acsnano.5b02014
190. Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, Davidson MG, Kenkel JA, Segal E, Pusapati GV, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 2015; 521:99-104; PMID:25924063; https://doi.org/10.1038/nature14424
191. Vandenberk L, Garg AD, Verschuere T, Koks C, Belmans J, Beullens M, Agostinis P, De Vleeschouwer S, Van Gool SW. Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology 2016; 5:e1083669; PMID:27057467; https://doi.org/10.1080/2162402X.2015.1083669
192. Lu L, Tao H, Chang AE, Hu Y, Shu G, Chen Q, Egenti M, Owen J, Moyer JS, Prince ME, et al. Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. Oncoimmunology 2015; 4:e990767; PMID:25949905; https://doi.org/10.4161/2162402X.2014.990767
193. Jung ID, Shin SJ, Lee MG, Kang TH, Han HD, Lee SJ, Kim WS, Kim HM, Park WS, Kim HW, et al. Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X. J Immunol 2014; 193:1233-45; PMID:24990079; https://doi.org/10.4049/jimmunol.1400656
194. Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, et al. Engineering monocyte-derived dendritic cells to secrete interferon-alpha enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunol Immunother 2015; 64:831-42; PMID:25863943; https://doi.org/10.1007/s00262-015-1688-2
195. Martin K, Muller P, Schreiner J, Prince SS, Lardinois D, Heinzelmann-Schwarz VA, Thommen DS, Zippelius A. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol Immunother 2014; 63:925-38; PMID:24906866; https://doi.org/10.1007/s00262-014-1565-4
196. Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N, Cursiefen C, Fuisting B, Grisanti S, Heindl LM, Holbach L, Keserü M, Knorr H, et al. Immunotherapy of uveal melanoma:Vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma. Ophthalmologe 2015; 112:1017-21; PMID:26602097; https://doi.org/10.1007/s00347-015-0162-z
197. Hunn MK, Bauer E, Wood CE, Gasser O, Dzhelali M, Ancelet LR, Mester B, Sharples KJ, Findlay MP, Hamilton DA, et al. Dendritic cell vaccination combined with temozolomide retreatment:Results of a phase I trial in patients with recurrent glioblastoma multiforme. J Neurooncol 2015; 121:319-29; PMID:25366363; https://doi.org/10.1007/s11060-014-1635-7
198. Poschke I, Lovgren T, Adamson L, Nystrom M, Andersson E, Hansson J, Tell R, Masucci GV, Kiessling R. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother 2014; 63:1061-71; PMID:24993563; https://doi.org/10.1007/s00262-014-1575-2
199. Baek S, Kim YM, Kim SB, Kim CS, Kwon SW, Kim Y, Kim H, Lee H. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients:A phase I/II trial. Cell Mol Immunol 2015; 12:87-95; PMID:24976269; https://doi.org/10.1038/cmi.2014.40
200. Ahrens ET, Helfer BM, O'Hanlon CF, Schirda C. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. Magn Reson Med 2014; 72:1696-701; PMID:25241945; https://doi.org/10.1002/mrm.25541 10.1002/mrm.25454
201. Wang H, Feng F, Zhu M, Wang R, Wang X, Wu Y, Zhuang Z. Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma. Xi bao yu fen zi mian yi xue za zhi 2015; 31:67-71; PMID:25575061
202. Hsu MS, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, Du L, Emerson R, Yusko E, Sanders C, et al. TCR sequencing can identify and track glioma-infiltrating T cells after DC vaccination. Cancer Immunol Res 2016; 4:412-8; PMID:26968205; https://doi.org/10.1158/2326-6066.CIR-15-0240
203. Zhao X, Zhang Z, Li H, Huang J, Yang S, Xie T, Huang L, Yue D, Xu L, Wang L, et al. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett 2015; 362:192-8; PMID:25843292; https://doi.org/10.1016/j.canlet.2015.03.043
204. Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, et al. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015; 111:862-7; PMID:25873455; https://doi.org/10.1002/jso.23897
205. Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C. Dendritic versus tumor cell presentation of autologous tumor antigens for active specific immunotherapy in metastatic melanoma:Impact on long-term survival by extent of disease at the time of treatment. Cancer Biother Radiopharm 2015; 30:187-94; PMID:26083950; https://doi.org/10.1089/cbr.2015.1843
206. Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2015; 6:18192-205; PMID:26078335; https://doi.org/10.18632/oncotarget.4145
207. Zhao P, Bu X, Wei X, Sun W, Xie X, Li C, Guo Q, Zhu D, Wei X, Gao D. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. Int Immunopharmacol 2015; 25:450-6; PMID:25698555; https://doi.org/10.1016/j.intimp.2015.02.010
208. Rexer H. [Study and therapy of metastatic castration-resistant prostate cancer:A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for first line chemotherapy (VIABLE) - AUO study AP 78/13]. Urologe A 2015; 54:555-7; PMID:25758238; https://doi.org/10.1007/s00120-015-3801-8
209. Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, et al. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J Gastroenterol 2015; 21:11168-78; PMID:26494971; https://doi.org/10.3748/wjg.v21.i39.11168
210. Qiu Y, Yun MM, Dong X, Xu M, Zhao R, Han X, Zhou E, Yun F, Su W, Liu C, et al. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic alpha-1,3 galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy. Cytotherapy 2016; 18:91-8; PMID:26549382; https://doi.org/10.1016/j.jcyt.2015.09.012
211. Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH, Lee H, Yi NJ, Lee KW, Suh KS, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 2015; 113:1666-76; PMID:26657650; https://doi.org/10.1038/bjc.2015.430
212. Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D'Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C, et al. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother 2015; 38:71-6; PMID:25658616; https://doi.org/10.1097/CJI.0000000000000063
213. Bol KF, Mensink HW, Aarntzen EH, Schreibelt G, Keunen JE, Coulie PG, de Klein A, Punt CJ, Paridaens D, Figdor CG, et al. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. Am J Ophthalmol 2014; 158:939-47; PMID:25038326; https://doi.org/10.1016/j.ajo.2014.07.014
214. Zhang L, Xu Y, Shen J, He F, Zhang D, Chen Z, Duan Y, Sun J. Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Radiat Oncol 2016; 11:60; PMID:27097970; https://doi.org/10.1186/s13014-016-0635-5
215. Xi HB, Wang GX, Fu B, Liu WP, Li Y. Survivin and PSMA loaded dendritic cell vaccine for the treatment of prostate cancer. Biol Pharm Bull 2015; 38:827-35; PMID:25787895; https://doi.org/10.1248/bpb.b14-00518
216. Narita M, Kanda T, Abe T, Uchiyama T, Iwafuchi M, Zheng Z, Liu A, Kaifu T, Kosugi S, Minagawa M, et al. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. Int J Oncol 2015; 46:1699-709; PMID:25625346; https://doi.org/10.3892/ijo.2015.2846
217. Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, Higuchi H, Taguchi J, Takeuchi H, Itano O, Aiura K, et al. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci 2015; 106:397-406; PMID:25614082; https://doi.org/10.1111/cas.12621
218. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother 2015; 64:1251-60; PMID:26105625; https://doi.org/10.1007/s00262-015-1731-3
219. Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y, Koya T, Ochiai T, Koide M, Uehara S, et al. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. J Neurosurg 2015; 123:989-97; PMID:26252465; https://doi.org/10.3171/2015.1.JNS141554
220. Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, Tokumitsu Y, Hashimoto N, Tokuhisa Y, Sakamoto K, Sakai K, et al. Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma:A phase 1 dose escalation clinical trial. Cancer Immunol Immunother 2015; 64:1047-56; PMID:25982372; https://doi.org/10.1007/s00262-015-1709-1
221. Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother 2015; 64:381-8; PMID:25548092; https://doi.org/10.1007/s00262-014-1642-8
222. Si Y, Deng Z, Lan G, Du H, Wang Y, Si J, Wei J, Weng J, Qin Y, Huang B, et al. The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients:A phase I clinical trial and two-year follow-up. Chem Pharm Bull 2016; 64:1118-23; PMID:27477649; https://doi.org/10.1248/cpb.c16-00114
223. Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, Macchia I, Aricò E, Casorelli I, Sestili P, et al. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity:Results from a phase I trial in advanced melanoma. J Transl Med 2015; 13:139; PMID:25933939; https://doi.org/10.1186/s12967-015-0473-5
224. Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, et al. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood 2015; 125:82-9; PMID:25293773; https://doi.org/10.1182/blood-2014-07-592162
225. Zhao X, Ji CY, Liu GQ, Ma DX, Ding HF, Xu M, Xing J. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy. Int J Clin Exp Pathol 2015; 8:13146-55; PMID:26722513
226. Yan L, Wu M, Ba N, Wang LJ, Zhang HQ, Shi GY, Zhang ZS, Wang XJ. Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma. Genet Mol Res 2015; 14:898-905; PMID:25730028; https://doi.org/10.4238/2015.February.2.13
227. Greene JM, Schneble EJ, Jackson DO, Hale DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X, et al. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. Cancer Immunol Immunother 2016; 65:383-92; PMID:26894495; https://doi.org/10.1007/s00262-016-1809-6
228. Ho VT, Kim HT, Kao G, Cutler C, Levine J, Rosenblatt J, Joyce R, Antin JH, Soiffer RJ, Ritz J, et al. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2014; 89:1092-6; PMID:25132538; https://doi.org/10.1002/ajh.23825
229. Saito S, Yanagisawa R, Yoshikawa K, Higuchi Y, Koya T, Yoshizawa K, Tanaka M, Sakashita K, Kobayashi T, Kurata T, et al. Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia:A case report and review of the literature. Cytotherapy 2015; 17:330-5; PMID:25484308; https://doi.org/10.1016/j.jcyt.2014.10.003
230. Kimura H, Matsui Y, Ishikawa A, Nakajima T, Yoshino M, Sakairi Y. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunol Immunother 2015; 64:51-9; PMID:25262164; https://doi.org/10.1007/s00262-014-1613-0
231. Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 2016; 34:1330-8; PMID:26926680; https://doi.org/10.1200/JCO.2015.63.4121
232. van den Hout MF, Sluijter BJ, Santegoets SJ, van Leeuwen PA, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node. Cancer Immunol Immunother 2016; 65:405-15; PMID:26935057; https://doi.org/10.1007/s00262-016-1811-z
233. Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, et al. Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF:Recruitment and activation of BDCA3/CD141(+) dendritic cells and enhanced cross-presentation. Cancer Immunol Res 2015; 3:495-505; PMID:25633713; https://doi.org/10.1158/2326-6066.CIR-14-0165
234. Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, Sartorius-Mergenthaler S, Freed I, Ravi S, Wang H, et al. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med 2015; 13:214; PMID:26143264; https://doi.org/10.1186/s12967-015-0572-3
235. Wilgenhof S, Corthals J, Heirman C, Baren, Nv, Lucas S, Kvistborg P, Thielemans K, Neyns B. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 2016; 34:1330-8; PMID:26926680; https://doi.org/10.1200/JCO.2015.63.4121
236. Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, et al. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J Gastroenterol 2015; 21:11168-78; PMID:26494971; https://doi.org/10.3748/wjg.v21.i39.11168
237. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; https://doi.org/10.1146/annurev-immunol-032712-100008
238. Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies:A large-scale meta-analysis. Oncoimmunology 2016; 5:e1069938; PMID:27057433; https://doi.org/10.1080/2162402X.2015.1069938
239. Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, et al. Trial watch:Dendritic cell-based anticancer therapy. Oncoimmunology 2014; 3:e963424; PMID:25941593; https://doi.org/10.4161/21624011.2014.963424
240. Bol KF, Aarntzen EHJG, Hout, FEMit, Schreibelt G, Creemers JHA, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, et al. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology 2016; 5:e1057673; PMID:26942068; https://doi.org/10.1080/2162402X.2015.1057673
241. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, et al. Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology 2016; 5:e1145332; PMID:27471611; https://doi.org/10.1080/2162402X.2016.1145332
242. Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T. Perspectives on sipuleucel-T:Its role in the prostate cancer treatment paradigm. OncoImmunology 2016; 5:e1107698; PMID:27141392; https://doi.org/10.1080/2162402X.2015.1107698
243. Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N. PD-1 expression conditions T cell avidity within an antigen-specific repertoire. OncoImmunology 2016; 5:e1104448; PMID:26942093; https://doi.org/10.1080/2162402X.2015.1104448
244. Chevalier MF, Bobisse S, Costa-Nunes C, Cesson V, Jichlinski P, Speiser DE, Harari A, Coukos G, Romero P, Nardelli-Haefliger D, et al. High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. OncoImmunology 2015; 4:e1029702; PMID:26451296; https://doi.org/10.1080/2162402X.2015.1029702
245. Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology 2016; 5:e1240859; PMID:28123878; https://doi.org/10.1080/2162402X.2016.1240859